Aquestive Therapeutics, Inc.
NASDAQ:AQSTDrug Manufacturers - Specialty & Generic
+$0.23 today
- Market cap
- $475.10M
- Beta
- 1.45
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.56
Volume 1.80M
Average 1.51M
AQST Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Aquestive Therapeutics, Inc.NASDAQ: AQST
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $113K fell 18.7% year over year, ahead of the -19.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 13.1% from the prior quarter. Over 3 fiscal years it compounded at -38.8% a year.
Context
- Depreciation & amortization amounted to 1.2% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -18.7% holds above the trailing-twelve-month pace of -19.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 548K USD
- Year-over-year change
- -23.7%
- 4-year CAGR
- -34.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 548K | -23.7% |
| FY2024 | 2024-12-31 | 718K | -46.6% |
| FY2023 | 2023-12-31 | 1.35M | -43.7% |
| FY2022 | 2022-12-31 | 2.39M | -19.5% |
| FY2021 | 2021-12-31 | 2.96M | — |
Depreciation & Amortization vs competitors
How AQST compares with its peers on the latest reported figures
- AQST's LTM Mar 2026 depreciation & amortization of $522K is the smallest of the 10 companies compared; the peer median is $12.47M.
- Its year-over-year change of -19.7% is the 9th highest of 10, against a peer median of +17.1%.
- Depreciation & amortization amounts to 1.0% of revenue for AQST, versus a peer median of 6.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $227.86M | +19.7% | +16.7% | 28.6% | |
| LTM Jun 2026 | $101.71M | +26.1% | +2.3% | 12.2% | |
| LTM Sep 2026 | $80.71M | +167.6% | -29.6% | 4.6% | |
| LTM Mar 2026 | $57.48M | +44.0% | +30.0% | 8.0% | |
| LTM Mar 2026 | $12.47M | +3.0% | -1.4% | 4.0% | |
| LTM Mar 2026 | $8.66M | +9.7% | — | 4.0% | |
| LTM Mar 2026 | $5.25M | -11.5% | -0.3% | 12.5% | |
| LTM Mar 2026 | $4.41M | +17.1% | +2.7% | 6.8% | |
| LTM Mar 2026 | $2.77M | -57.2% | +62.5% | 2.3% | |
| LTM Mar 2026 | $522K | -19.7% | -38.8% | 1.0% | |
| Peer median (excluding AQST) | $12.47M | +17.1% | +2.5% | 6.8% | |
Competitors are the stored peer set for AQST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (70.54M) | (54.41M) | (7.87M) | (44.14M) | (83.78M) |
| Depreciation & Amortization | 2.96M | 2.39M | 1.35M | 718K | 548K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.82M | 4.38M | 2.69M | 7.1M | 7.62M |
| Change in Working Capital | (1.73M) | 32.01M | (5.34M) | (9.96M) | 12.18M |
| Accounts Receivables | (5.35M) | 7.35M | (3.07M) | 1.09M | (10.37M) |
| Inventory | (1.58M) | (1.74M) | (989K) | 725K | (126K) |
| Accounts Payables | 1.23M | 1.63M | (1.02M) | 2.78M | 19.52M |
| Other Working Capital | 3.98M | 24.77M | (259K) | (14.56M) | 3.16M |
| Other Non-Cash Items | 29.51M | 5.85M | 2.8M | 10.52M | 11M |
| Operating Cash Flow | (32.98M) | (9.79M) | (6.38M) | (35.76M) | (52.43M) |
| Capital Expenditures | (913K) | (2.52M) | (995K) | (159K) | (562K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (913K) | (2.52M) | (995K) | (159K) | (562K) |
| Debt Repayment | 0 | (2.03M) | (20.39M) | (23K) | (37K) |
| Common Stock Issued | 29.78M | 13.59M | 8.91M | 83.76M | 103.46M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 329K | 1K | 15.45M | (142K) | (810K) |
| Financing Cash Flow | 30.11M | 11.56M | 3.97M | 83.59M | 102.62M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (3.78M) | (751K) | (3.4M) | 47.67M | 49.62M |
| Free Cash Flow | (33.89M) | (12.31M) | (7.38M) | (35.92M) | (52.99M) |
Aquestive Therapeutics, Inc.
NASDAQ:AQST
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.